First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors
Recruiting · Phase 1, Phase 2 · NCT05875168
Conditions: Advanced Solid Tumor, Metastatic Solid Tumor
At a glance
- Research payments reported, 2025
- $5.7M
- U.S. investigators named
- 7
- Sites paid
- 8
- Planned or actual enrollment
- 590
About the trial
- Sponsor
- Daiichi Sankyo
- Tested
- DS-3939a (drug)
- Dates
- Started 2023-08-18; completion 2028-11-11
- Results posted
- Not yet
This study will evaluate the safety, tolerability, and efficacy of DS-3939a in participants with advanced solid tumors.
From ClinicalTrials.gov, last updated 2026-10-15. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Daiichi Sankyo Inc. reported $5.7M in research payments for this study in 2025 (3,824 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Ignacio Garrido-laguna, MD Medical Oncology · Tampa, FL
- Manish R. Patel, MD Medical Oncology · Sarasota, FL
- Ben George, M.D. Medical Oncology · Rochester, MN
- Shivaani Kummar Medical Oncology · Portland, OR
- Benedito A. Carneiro, MD Medical Oncology · Providence, RI
- Sarina A. Piha-paul, M.D. Medical Oncology · Houston, TX
- Mandana Kamgar, M.D. Hematology & Oncology · Milwaukee, WI
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Rhode Island Hospital, RI $2.4M
- Sarah Cannon Research Institute $1.9M
- Ut MD Anderson Cancer Center $785,074
- University of Utah Hospital and Clinics, UT $302,049
- Ohsu Hospital and Clinics, OR $172,734
- Medical College of Wisconsin $95,351
- Florida Cancer Specialists and Research Institute Sarasota Cattlemen $7,202
- Froedtert Memorial Lutheran Hospital, WI $168
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.